Equillium Q2 Loss Narrows to $4.69M, Beats Estimates; New R&D Programs Advance
EQ has more than doubled off its 52-week low of $0.756.
Summary
Equillium reported Q2 net loss of $4.69M, beating consensus of $5.91M, with loss per share of $0.04 vs $0.05 expected. The company also initiated IND-enabling development for EQ504 as an inhaled therapy and EQ302 for celiac disease, expanding its pipeline. Phase 1 EQ504 study is planned for Q4 2026 with data about six months later. Cash runway extends into 2029, consistent with prior guidance. This follows a reverse stock split approved in May and insider selling by the CSO in June, but the earnings beat and new R&D initiatives are fresh positive developments.
At the time of this announcement, EQ was trading at $2.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.1M. The 52-week trading range was $0.76 to $3.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.